ALX Oncology Holdings Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALXO research report →
Companywww.alxoncology.com
ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.
- CEO
- Jason W. Lettmann
- IPO
- 2020
- Employees
- 65
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $107.91M
- P/E
- -1.22
- P/S
- 0.00
- P/B
- 0.71
- EV/EBITDA
- -0.92
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -124.06%
- ROIC
- -55.81%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-101,695,000 · 24.59%
- EPS
- $-1.90 · 26.36%
- Op Income
- $-104,021,000
- FCF YoY
- 31.06%
Performance & Tape
- 52W High
- $2.66
- 52W Low
- $0.40
- 50D MA
- $1.91
- 200D MA
- $1.60
- Beta
- 0.41
- Avg Volume
- 886.55K
Get TickerSpark's AI analysis on ALXO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | Knight Jeff E. | other | 800,000 |
| Apr 16, 26 | Klencke Barbara | other | 100,000 |
| Apr 13, 26 | Knight Jeff E. | other | 0 |
| Mar 19, 26 | Lettmann Jason | sell | 12,311 |
| Mar 19, 26 | Pinto Shelly | sell | 903 |
| Mar 3, 26 | Klencke Barbara | other | 700,000 |
| Feb 25, 26 | Klencke Barbara | other | 0 |
| Feb 25, 26 | Klencke Barbara | other | 40,400 |
| Feb 25, 26 | Klencke Barbara | other | 300,000 |
| Feb 25, 26 | Klencke Barbara | other | 100,000 |
Our ALXO Coverage
We haven't published any research on ALXO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALXO Report →